Notably, some compounds have been developed to affect splicing control and have resulted in promising therapeutic agents [24], thus developing novel anticancer compounds targeting alternative splicing of CCDC50 might become eligible strategy for controlling cancers including ccRCC. The gene discussed is CCDC50; the disease is nonpapillary renal cell carcinoma.